MPM Capital Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Professionals
-
27

- Investments
-
384
- Portfolio
-
34
- Exits
-
228

MPM Capital General Information
Description
Founded in 1997, MPM Capital is a venture capital firm based in Cambridge, Massachusetts. The firm prefers to invest in seed-stage, early-stage, later-stage, and growth-stage companies. The firm prefers to invest in the biotechnology, healthcare, and life sciences sectors in the United States.
Contact Information
Investor Status
Actively Seeking New Investments
Trade Association
New England Venture Capital Association (NEVCA)
National Venture Capital Association (NVCA)
Primary Investor Type
Venture Capital
Other Investor Types
PE/Buyout
Primary Office
- 450 Kendall Street
- Cambridge, MA 02142
- United States
+1 (617) 000-0000
MPM Capital Investments & Acquisitions (384)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Cardiac Dimensions | 22-Dec-2022 | Later Stage VC | 0000 | Therapeutic Devices | Generating Revenue/Not Profitable | |
000000000 (0000 00 | 13-Dec-2022 | 00000 00000 | 0000 | Drug Discovery | Startup | 0000000 00000 00.0 |
000000 | 08-Sep-2022 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 000000 00000000 00 |
00000 00000000 | 18-Aug-2022 | 00000 00000 | 0000 | Drug Discovery | Pre-Clinical Trials | 0000000 00000 00.0 |
0000 000000000000 | 16-Aug-2022 | 00000 00000 | 00000 | Drug Delivery | Product Development | 0000000 0000000 00 |
000000 00000000000 | 29-Jun-2022 | 00000 00000 | 00000 | Drug Delivery | Generating Revenue | |
0000 0000000000000 | 02-Dec-2021 | 00000 00000 | 0000 | Drug Discovery | Out of Business | 0000 00000 |
00000 000000000000 | 08-Nov-2021 | 0000 | 0000 | Drug Discovery | Generating Revenue | 0000 00000 00.0 |
Protego Biopharma | 19-Oct-2021 | Later Stage VC | 0000 | Drug Discovery | Generating Revenue | 000000 0000000 |
Burrage Capital Management | 08-Jul-2021 | Merger/Acquisition | Private Equity | Generating Revenue | 0000000 0000000 00 |
MPM Capital Exits (228)
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
Triplet Therapeutics | 12-Oct-2022 | Out of Business | |
000000 00000000000 | 01-Jun-2022 | 000000000000000000 | |
0000000 0000000000 | 02-Nov-2021 | 000 | 00000 |
00000000 000000000 | 01-Oct-2021 | 000000000000000000 | 00000 |
000000 00000000000 | 30-Apr-2021 | 000 00 00000000 | |
00000000 000000000 | 30-Apr-2021 | 000 | 00000 |
000000 00000000000 | 24-Feb-2021 | 000 00 00000000 | |
0000000 | 12-Feb-2021 | 000000 0000000000 | 0000 |
Dyne Therapeutics | 21-Jan-2021 | Public Investment 2nd Offering | 00000 |
TCR2 Therapeutics | 21-Jan-2021 | Public Investment 2nd Offering | 00000 |
MPM Capital Fund Performance
Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
---|
MPM Capital Investments by Industry, Year, and Region
MPM Capital Team (96)
Name | Title | Deals | Funds | Boards | Office |
---|---|---|---|---|---|
Kristen Laguerre | Managing Director, Chief Financial Officer & Chief Operating Officer | 0 | 0 | Cambridge, MA | |
Ansbert Gadicke MD | Co-Founder & Managing Director | 00 | 00 | 0 | Cambridge, MA |
Luke Evnin Ph.D | Co-Founder & Managing Director | 00 | 00 | 0 | Brisbane, CA |
Bard Geesaman Ph.D | Managing Director | 00 | 0 | 0 | Cambridge, MA |
David Stack | Managing Director | 0 | 0 | 0 | Cambridge, MA |
MPM Capital Co-Investors (182)
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
Astellas Venture Management | 5 | 0 |
![]() |
![]() |
|
Cowen Healthcare Investments | 0 | 0 |
![]() |
![]() |
|
Deerfield Management | 0 | 0 | 0 |
![]() |
![]() |
F2 Ventures | 0 | 0 | 0 |
![]() |
![]() |
RA Capital Management | 0 | 0 |
![]() |
![]() |